Acorda Builds Ampyra Promotion On Years Of MS Outreach
Executive Summary
Acorda's challenge in marketing its multiple sclerosis drug Ampyra is not that it is a new drug, but that it is a new drug indicated to treat an aspect of the disease that has never before been treated
You may also be interested in...
Acorda R&D Day Explores Pipeline Opportunities
Acorda Therapeutics highlighted the other indications it has in the works for its MS drug Ampyra, as well as several early-stage compounds in other neurological indications.
Acorda R&D Day Explores Pipeline Opportunities
Acorda Therapeutics highlighted the other indications it has in the works for its MS drug Ampyra, as well as several early-stage compounds in other neurological indications.
Acorda Expands Pipeline With Neuronex And New Ampyra Indications
Acorda Therapeutics reports strong Ampyra results in the fourth quarter and highlights the other indications it’s pursuing for the drug, as well as the consumer marketing campaign the company is about to undertake. Acorda also announced its intention to acquire privately-held Neuronex Inc. for $2 million upfront plus $500,000 in R&D funding.